Compare Corning Incorporated (GLW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Sanofi SA — how do they compare? Corning Incorporated trades at $168.09 (market cap $137.12B), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Corning Incorporated is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| GLW | SNY | |
|---|---|---|
Market Cap | $137.12B | $104.30B |
Sector | Technology | Health |
52-Week High | $255.79 | $52.34 |
52-Week Low | $64.52 | $41.33 |
Enterprise Value | $144.00B | $124.19B |
Dividend Yield | 0.7% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLW trades at $166.95, up 5.84% in the last session, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.78, beating expectations, driven by 17% YoY core sales growth from optical and AI data center demand. Valuation ratios are elevated, with a P/E of 73.36 and P/S of 8.23, while profitability improved with a net income margin of 11.2% in 2025.
The outlook is supported by AI infrastructure growth and analyst optimism, with a consensus price target of $193.33 implying 16% upside. Risks include premium valuation sensitivity and execution challenges in scaling solar and optical segments. Cash flow is projected to turn positive in 2026, but debt-to-asset ratio remains elevated at 27.67%.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
